Heterocyclic Antidepressants with Antimicrobial and Fungicide Activity

Area of Science:

• Pharmacology
• Microbiology
• Neuroscience

Background:

• The gut microbiome's established link to mental health necessitates investigating factors that may disrupt it.
• Increasing microbial resistance to antibiotics presents a significant global health challenge.
• Heterocyclic antidepressants are widely prescribed, making their potential impact on microflora a critical area of study.

Purpose of the Study:

• To investigate the antimicrobial and fungicidal activities of heterocyclic antidepressants.
• To explore the potential of these antidepressants to disrupt the intestinal microflora.
• To assess the impact of antidepressants on bacteria known to influence mental health.

Main Methods:

• Review of existing literature on heterocyclic antidepressants and their biological activities.
• Analysis of studies reporting on the antimicrobial and fungicidal properties of these compounds.
• Examination of data regarding the effects of antidepressants on specific gut bacterial species.

Main Results:

• Most heterocyclic antidepressants reviewed demonstrated significant antimicrobial activity.
• These drugs were found to inhibit the growth of pathogenic microorganisms.
• Crucially, antidepressants also suppressed beneficial gut bacteria, including *Lactobacillus*, *Lactococcus*, *Streptococcus*, *Enterococcus*, and *Bifidobacterium*.

Conclusions:

• Heterocyclic antidepressants possess broad-spectrum antimicrobial properties.
• Their use may negatively affect the gut microbiome composition, including beneficial bacteria vital for mental health.
• Further research is warranted to understand the clinical implications of these findings for patients' gut health and overall well-being.